Barclays Maintains Exscientia(EXAI.US) With Buy Rating, Maintains Target Price $10
Barclays analyst Peter Lawson maintains $Exscientia(EXAI.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 44.1% and a total a
Barclays Keeps Their Buy Rating on Exscientia Plc (EXAI)
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon
Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I
Exscientia to Reduce Up to 25% Workforce by Year End
Exscientia (EXAI) said Tuesday that it expects to complete a headcount reduction of 20% to 25% by the end of 2024. The job cuts are part of cost efficiency measures that the company will initiate to s
Express News | Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results
Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers
Exscientia Advances AI-Driven Drug Pipeline, Cuts Costs
Exscientia | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | Exscientia's Cash, Cash Equivalents And Short-term Bank Deposits As Of March 31, 2024 Were $416.9M, Which Is Expected To Provide Cash Runway Into 2027
Express News | Exscientia PLC - as Part of Measures, 20-25% Headcount Reduction Expected to Be Completed by End of 2024
Express News | Exscientia PLC - Efficiency Measures Expect to Result in Annualised Savings of $40 Mln or More Beginning in 2025
Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI
Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI
Exscientia 1Q Rev $6.7M >EXAI
Exscientia 1Q Rev $6.7M >EXAI
Express News | Exscientia PLC - Will Initiate Efficiency Measures Through Rest of Year Designed to Streamline Co’s Ops
Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M
07:04 AM EDT, 05/21/2024 (MT Newswires) -- Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M
Express News | Exscientia Q1 2024 GAAP EPS $(0.21) Beats $(0.39) Estimate, Sales $6.700M Miss $7.509M Estimate
Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI
Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI
Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI
Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI
Express News | Exscientia PLC Q1 Revenue USD 6.7 Million
Express News | Exscientia PLC Q1 Operating Cash Flow USD 39 Million